Deciphering the selectivity of CBL-B inhibitors using all-atom molecular dynamics and machine learning

24 August 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We employ a combination of accelerated molecular dynamics and machine learning techniques to unravel the dynamic characteristics of CBL-B and C-CBL, and how their configurational changes conferring the binding affinity and selectivity of their ligands. We demonstrate that the activity and selectivity against CBL-B and C stem from subtle structural disparities within their binding pockets, and dissociation pathways. Our predictive model for dissociation rate constants (koff) demonstrates a moderate correlation with experimental IC50 values, effectively aligning with two available experimental koff values. Moreover, the binding free energies calculated using MM/GBSA highlight the ΔG distinction between CBL-B and C-CBL. By employing a regression strategy on dissociation trajectories, we identified key amino acids in binding pocket and along the dissociation path responsible for activity and selectivity. These amino acids are statistically significant in achieving activity and selectivity and correspond to the primary structural discrepancies between CBL-B and C-CBL. Through microsecond-scale replica exchange molecular dynamics coupled with generative model of molecular generation and ensemble docking, we accomplish comprehensive simulations of the complete apo-holo-apo transformation cycle. This approach provides an enabling first-in-class drug design technology based on apo-to-holo structure transformation.

Keywords

koff
MD
drug design
ML

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.